Hakimi Sevil, Lami Faris, Allahqoli Leil, Alkatout Ibrahim
Tabriz University of Medical Science, Research Center of Psychiatry and Behavioral Sciences, Tabriz, Iran
Department of Family and Community Medicine, College of Medicine, University of Baghdad, Baghdad, Iraq
J Turk Ger Gynecol Assoc. 2023 Mar 15;24(1):48-56. doi: 10.4274/jtgga.galenos.2022.2022-6-6. Epub 2022 Dec 30.
The human papillomavirus (HPV) vaccine is regarded as one of the most effective ways of preventing cervical cancer. Despite the massive burden of this disease, only two countries in the Eastern Mediterranean Region (EMR) have implemented a national HPV vaccination program. The aim of the present study was to assess the main barriers to the integration of HPV vaccination in the national vaccination programs of EMR countries.
We performed a narrative review with no inclusion and exclusion criteria. The electronic databases we searched included Medline, Scopus, Embase, and Web of Science (last update; December 2021). The search was not subject to any limitation in terms of time or method. Studies that dealt with the obstacles or the needs of vaccination programs in EMR countries were included in the investigation.
After a full-text screening, the report comprised of 31 studies from 15 EMR countries. All of the studies were descriptive. The most common barriers to HPV vaccination are the following: a) lack of knowledge and awareness, b) economic barriers in terms of the cost-effectiveness of the HPV vaccination program, c) social insecurity in conflict zones, d) cultural norms and religion.
EMR countries should focus on modifiable barriers to the vaccination program. Steps to improve HPV vaccination coverage in these countries should include enhancing social awareness and mobilization, ensuring the support of the Global Alliance for Vaccines and Immunization in eligible countries, using national resources in an optimal way, and addressing HPV vaccination in undergraduate medicine and paramedic curriculums.
人乳头瘤病毒(HPV)疫苗被视为预防宫颈癌最有效的方法之一。尽管该疾病负担沉重,但东地中海区域(EMR)仅有两个国家实施了全国性HPV疫苗接种计划。本研究的目的是评估EMR国家将HPV疫苗接种纳入国家疫苗接种计划的主要障碍。
我们进行了一项无纳入和排除标准的叙述性综述。我们检索的电子数据库包括Medline、Scopus、Embase和科学网(最后更新时间:2021年12月)。检索在时间或方法上没有任何限制。涉及EMR国家疫苗接种计划障碍或需求的研究被纳入调查。
经过全文筛选,该报告包含来自15个EMR国家的31项研究。所有研究均为描述性研究。HPV疫苗接种最常见的障碍如下:a)知识和意识缺乏,b)HPV疫苗接种计划成本效益方面的经济障碍,c)冲突地区的社会不安全因素,d)文化规范和宗教。
EMR国家应关注疫苗接种计划中可改变的障碍。提高这些国家HPV疫苗接种覆盖率的措施应包括提高社会意识和动员能力,确保符合条件的国家获得全球疫苗免疫联盟的支持,以最佳方式利用国家资源,以及在本科医学和护理课程中纳入HPV疫苗接种内容。